- MilliporeSigma will acquire the chromatography business of JSR Life Sciences to enhance its downstream processing capabilities.
- The transaction is expected to close by the end of the second quarter of 2026.
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has agreed to acquire the chromatography business of JSR Life Sciences. The acquisition aims to expand MilliporeSigma’s downstream processing portfolio with advanced Protein A chromatography technologies.
The deal will support more efficient and scalable production of biopharmaceutical therapies, including monoclonal antibodies. According to the announcement, the transaction is expected to close by the end of the second quarter of 2026.
“This acquisition will strengthen our position in the bioprocessing market and underscores our commitment to long-term investment in monoclonal antibody production technologies.”
Sebastián Arana, Head of Process Solutions, Life Science business of Merck KGaA, Darmstadt, Germany.
Based in Belgium, JSR Life Sciences’ chromatography business employs more than 50 people and supplies chromatography solutions to pharmaceutical and biotech manufacturers worldwide. Its Amsphere A3 and Amsphere A+ Protein A resins are recognised for their high purification performance and process robustness.
“The move positions our innovative Amsphere Protein A technologies for even greater global impact under Merck’s renowned platform—enabling more customers worldwide to accelerate therapies to market with enhanced speed and confidence.”
Tim Lowery, President of JSR Life Sciences
